The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study

References

• Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–1380. doi:10.1056/NEJMra0802714
   PubMed Web of Science ®Google Scholar
• Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. doi:10.1038/s41572-020-00235-0
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12(1):47. doi:10.1186/s13045-019-0736-3
   PubMed Web of Science ®Google Scholar
• Reck M, Horn L, Novello S, et al. Phase II study of roniciclib in combination with cisplatin/Etoposide or carboplatin/Etoposide as first-line therapy in patients with extensive-disease small cell lung cancer. J Thorac Oncol. 2019;14(4):701–711. doi:10.1016/j.jtho.2019.01.010
   PubMed Web of Science ®Google Scholar
• Esposito G, Palumbo G, Carillio G, et al. Immunotherapy in small cell lung cancer. Cancers. 2020;12(9). doi:10.3390/cancers12092522.
   Web of Science ®Google Scholar
• Garst J. Topotecan: an evolving option in the treatment of relapsed small cell lung cancer. Ther Clin Risk Manag. 2007;3(6):1087–1095.
   PubMedGoogle Scholar
• De Jong WK, Ten Hacken NH, Groen HJ. Third-line chemotherapy for small cell lung cancer. Lung Cancer. 2006;52(3):339–342. doi:10.1016/j.lungcan.2006.02.005
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676. doi:10.1038/nm0603-669
   PubMed Web of Science ®Google Scholar
• Zhan P, Wang J, Lv XJ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009;4(9):1094–1103. doi:10.1097/JTO.0b013e3181a97e31
   PubMed Web of Science ®Google Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. doi:10.1186/s13045-018-0664-7
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang Q, Li K, et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. Br J Cancer. 2021;125(3):366–371. doi:10.1038/s41416-021-01356-3
   PubMed Web of Science ®Google Scholar
• Kong TD, Chen L, Duan FF, et al. Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): the final results from a phase II single-arm trial. J Clin Oncol. 2021;39(15):8560. doi:10.1200/JCO.2021.39.15_suppl.8560
   Web of Science ®Google Scholar
• Nabhan C, Klink A, Prasad V. Real-world evidence-What does it really mean?. JAMA Oncol. 2019;5(6):781–783. doi:10.1001/jamaoncol.2019.0450
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Pujol JL, Lavole A, Quoix E, et al. Randomized Phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. Ann Oncol. 2015;26(5):908–914. doi:10.1093/annonc/mdv065
   PubMed Web of Science ®Google Scholar
• Sharma N, Pennell N, Nickolich M, et al. Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Invest New Drugs. 2014;32(2):362–368. doi:10.1007/s10637-013-0061-6
   PubMed Web of Science ®Google Scholar
• Han JY, Kim HY, Lim KY, et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer. 2013;79(2):137–142. doi:10.1016/j.lungcan.2012.09.019
   PubMed Web of Science ®Google Scholar
• Montanino A, Manzo A, Carillio G, et al. Angiogenesis inhibitors in small cell lung cancer. Front Oncol. 2021;11:655316. doi:10.3389/fonc.2021.655316
   PubMed Web of Science ®Google Scholar
• Deng P, Yang H, Chen C, et al. The efficacy and safety profile of anlotinib with etoposide plus cisplatin/carboplatin in treatment-naive extensive-stage small cell lung cancer(SCLC) patients: results from a phase II single-arm trial. J Clin Oncol. 2020;38(15):9066. doi:10.1200/JCO.2020.38.15_suppl.9066
   Web of Science ®Google Scholar
• Han B, Zhang W, Zhang B, et al. Anlotinib plus etoposide and carboplatin as first-line treatment for extensive-stage small cell lung cancer: a single arm phase II trial. J Thorac Oncol. 2021;16(3):S503–S503. doi:10.1016/j.jtho.2021.01.879
   Web of Science ®Google Scholar
• Alshangiti A, Chandhoke G, Ellis PM. Antiangiogenic therapies in non-small-cell lung cancer. Curr Oncol. 2018;25(Suppl 1):S45–s58. doi:10.3747/co.25.3747
   PubMed Web of Science ®Google Scholar
• Yang Y, Li L, Jiang Z, et al. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother. 2020;69(12):2523–2532. doi:10.1007/s00262-020-02641-5
   PubMed Web of Science ®Google Scholar
• Liu S, Qin T, Liu Z, et al. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11(5):309. doi:10.1038/s41419-020-2511-3
   PubMed Web of Science ®Google Scholar
• Wang HY, Chu JF, Zhao Y, et al. A trial of the safety and efficacy of chemotherapy plus anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer. Cancer Manag Res. 2020;12:3827–3834. doi:10.2147/CMAR.S249678
   PubMed Web of Science ®Google Scholar
• Li T, Qian Y, Zhang C, et al. Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo. Transl Lung Cancer Res. 2021;10(4):1873–1888. doi:10.21037/tlcr-21-192
   PubMed Web of Science ®Google Scholar
• Picardi C, Caparroti F, Di Maio M, et al. Prophylactic cranial irradiation in extensive disease small cell lung cancer: an endless debate. Crit Rev Oncol Hematol. 2019;143:95–101. doi:10.1016/j.critrevonc.2019.08.010
   PubMed Web of Science ®Google Scholar
• Ansiaux R, Dewever J, Grégoire V, et al. Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy. Radiat Res. 2009;172(5):584–591. doi:10.1667/RR1744.1
   PubMed Web of Science ®Google Scholar
• Song PF, Xu N, Li Q. Efficacy and safety of anlotinib for elderly patients with previously treated extensive-stage SCLC and the prognostic significance of common adverse reactions. Cancer Manag Res. 2020;12:11133–11143. doi:10.2147/CMAR.S275624
   PubMed Web of Science ®Google Scholar
• Han JY, Kim HY, Lim KY, et al. A phase II study of nintedanib in patients with relapsed small cell lung cancer. Lung Cancer. 2016;96:108–112. doi:10.1016/j.lungcan.2016.04.002
   PubMed Web of Science ®Google Scholar
• Gao X, Peng L, Zhang L, et al. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer. J Cancer Res Clin Oncol. 2021. doi:10.1007/s00432-021-03848-4
   Web of Science ®Google Scholar
• Syed YY. Anlotinib: first global approval. Drugs. 2018;78(10):1057–1062. doi:10.1007/s40265-018-0939-x
   PubMed Web of Science ®Google Scholar